Systematic Reviews
Copyright ©The Author(s) 2023.
World J Hepatol. Jun 27, 2023; 15(6): 841-849
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.841
Table 1 The baseline patient parameters, n (%)
Variables
Number of patients (n = 27)
Age (± SD), yr72.7 (± 11.4)
SexFemales, 13 (48.1)
Males, 13 (48.1)
Not mentioned, 1 (3.7)
Country of originSwitzerland, 12 (44.4)
Italy, 4 (14.8)
United States of America, 4 (14.8)
France, 3 (11.1)
Australia, 1 (3.7)
Canada, 1 (3.7)
Ireland, 1 (3.7)
Spain, 1 (3.7)
Clinical presentationJaundice, 15 (55.6)
Malaise, 9 (33.3)
Vomiting, 9 (33.3)
Abdominal pain, 3 (11.1)
Itching, 3 (11.1)
Anorexia, 2 (7.4)
Fatigue, 2 (7.4)
Dyspepsia, 1 (3.7)
Breathlessness, 1 (3.7)
Pruritus, 1 (3.7)
Weight loss, 1 (3.7)
ComorbiditiesHypertension, 6 (22.2)
Diabetes, 3 (11.1)
Coronary artery disease, 3 (11.1)
Others, 6 (22.2)
Other drugs causing liver injuryNone, 11 (40.7)
Statins, 4 (14.8)
Not mentioned, 12 (44.4)
DOACs implicatedRivaroxaban, 20 (74.1)
Apixaban, 4 (14.8)
Dabigatran, 3 (11.1)
Indications of DOACsAtrial fibrillation, 13 (48.1)
Pulmonary embolism, 2 (7.4)
Transient ischemic attack, 1 (3.7)
Anti-phospholipid antibody syndrome, 1 (3.7)
Deep vein thrombosis, 1 (3.7)
Major lower limb surgery, 1 (3.7)
Sinus node dysfunction, 1 (3.7)
Accidental, 1 (3.7)
Time to presentation after initiation of DOACs (d)40.6 ± 42.8
Need for organ supportRenal replacement therapy, 1 (3.7)
Vasopressors, 1 (3.7)
Invasive mechanical ventilation, 1 (3.7)
Need for specific antidoteIdarucizumab, 1 (3.7)
Days in hospital (d)8 ± 9.3
Days in ICU (d)7 ± 12.1
OutcomeAlive, 26 (96.3)
Death, 1 (3.7)
Table 2 Liver function test parameters
Parameter
Mean
Standard deviation
Range
SGOT, at presentation (units/L)575.5672.290-2304
SGPT, at presentation (units/L)800.21159.690-4000
Total bilirubin, at presentation (mg/dl)6.360.64-21.8
Direct bilirubin, at presentation (mg/dl)4.84.90.3-10.3
Alkaline phosphatase, at presentation (units/L)269.2279.560-1039